Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.

ABSTRACT:

Importance

Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and could serve as a suitable target for synaptic density.

Objective

To compare hippocampal synaptic vesicle glycoprotein 2A (SV2A) binding in participants with AD and cognitively normal participants using positron emission tomographic (PET) imaging.

Design, setting, and participants

This cross-sectional study recruited 10 participants with AD and 11 participants who were cognitively normal between November 2015 a

SUBMITTER: Chen MK 

PROVIDER: S-EPMC6233853 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature